Can Telehealth Prescribe Peptides? Which Ones, in Which States

Key takeaways

• Yes, telehealth can prescribe the peptides that are FDA-approved or legally compoundable: semaglutide and tirzepatide (brand, or compounded only for a documented individual need), tesamorelin (brand Egrifta only), sermorelin, bremelanotide (PT-141), glutathione and NAD+.
• No telehealth platform, and no in-person clinic, can legally prescribe BPC-157, TB-500, KPV, MOTS-c, CJC-1295, ipamorelin or AOD-9604 in October 2026, because no licensed pharmacy may compound them.
• The clinician must be licensed in the state where you are during the visit, and some states require a live video or phone visit before a first prescription; the parent hub has the state table.
• Testosterone is the exception that follows different rules: it is a Schedule III controlled substance, prescribable by telehealth after a live video visit only under DEA flexibilities that run through December 31, 2026.

Yes, telehealth can prescribe peptides, but only the ones a pharmacy can legally supply: semaglutide and tirzepatide (brand, or compounded only for a documented individual need), tesamorelin (brand Egrifta only), sermorelin, bremelanotide (PT-141), glutathione and NAD+. It cannot prescribe BPC-157, TB-500, KPV, MOTS-c, CJC-1295, ipamorelin or the other non-compoundable peptides, on any platform, because no licensed pharmacy may make them. How licensure, live-visit rules and pharmacy shipping work state by state is in our hub on getting a peptide prescription online; whether a given compound fits you is in who qualifies for peptide therapy.

The answer, compound by compound

Statuses follow our legal tracker as of October 2026.

Why no platform can prescribe the 'No' rows

A telehealth prescription is legally the same object as one written in an office. What makes a peptide prescribable is the pharmacy's legal ability to fill it, and section 503A lets a pharmacy compound a bulk substance only if it has a USP monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list (FDA 503A list). Sermorelin and bremelanotide pass as components of approved drugs; glutathione is compounded instead under FDA's interim policy for Category 1 substances (FDA categories 2026). BPC-157, TB-500 and the rest pass none of the three. Tesamorelin is a different case: it is approved, but FDA regulates it as a biological product, and biological products are not eligible for compounding under 503A or 503B, so it is prescribed only as the brand, Egrifta.

The July 2026 votes are the source of most confusion. FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, epitalon and semax for the 503A list, over the objection of FDA's own reviewers, who cited missing human data and poorly characterized products (HPM 2026a). A recommendation is not a rule. FDA must publish a proposed rule, take comments and finalize it, and as of October 2026 none had appeared. For CJC-1295, ipamorelin and AOD-9604 the committee voted against in 2024 (FDA PCAC 2024), so there is not even a pending path.

That is why the flags in our clinic directory matter. On October 9, 2026, three of the twelve providers listed compounds no pharmacy may make: Defy Medical (BPC-157, TB-500, epithalon, KPV and MOTS-c), RegenMD Wellness (BPC-157, MOTS-c, AOD-9604, dihexa and injectable GHK-Cu, among others) and Ivy Rx (BPC-157 capsules), and Premier named AOD-9604 as an example of what a plan might include. Whatever the consultation looks like, those products cannot come from a licensed pharmacy filling a lawful prescription.

Brand and compounded: two routes for the 'Yes' rows

For the approved drugs, a telehealth clinician can send the prescription to any pharmacy, including a retail pharmacy covered by your insurance. Labels set the approved populations: Egrifta WR is indicated for excess abdominal fat in adults with HIV and lipodystrophy and is contraindicated in active malignancy and pregnancy (Egrifta WR label); Vyleesi is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder, not for men or postmenopausal women, and is contraindicated with uncontrolled hypertension or known cardiovascular disease (Vyleesi label). Prescribing outside the label is legal and common; it is the clinician's judgment, and it should be written down.

Compounded versions go to a state-licensed 503A pharmacy. Two limits apply. For semaglutide and tirzepatide, since the shortages ended, a compounded product is lawful only for a patient whose prescriber documents a clinical need the approved product cannot meet; price alone is not one. For bremelanotide, a compounded injection that simply mirrors Vyleesi needs a patient-specific reason, which is why compounded PT-141 usually comes as nasal sprays or other strengths. Sermorelin, glutathione and NAD+ have no brand, so compounding is the only route. If the prescription is for a vial, check the dose in syringe units with the peptide calculator.

Which states: the short version

The state question has three parts, all covered with citations on the parent hub.

• Licensure. The clinician must hold a license in the state where you are physically located during the visit; a national platform is a network of state licenses.
• Live visit or questionnaire. For non-controlled drugs, states decide. In the Center for Connected Health Policy's summaries, Arkansas, Kentucky, Mississippi, New Mexico, North Dakota, Rhode Island and West Virginia, among others, bar questionnaire-only prescribing or require a real-time exchange to start care, while California, Florida and Missouri allow asynchronous evaluation under conditions (CCHP). Providers often add their own live-visit requirements on top.
• Pharmacy licensing. The pharmacy must be licensed or registered in your state, and some states require extra permits for compounded injectables, which is why a compound can be 'not available in your state.'

The controlled-substance exception: testosterone

Peptides are not scheduled under the Controlled Substances Act. Testosterone, which men's health programs often sell alongside them, is listed in Schedule III (21 CFR 1308.13). That brings in the Ryan Haight Act of 2008, under which a controlled substance may be prescribed remotely only after at least one in-person medical evaluation, subject to listed exceptions (DEA, 90 FR 61301).

Since 2020, temporary DEA flexibilities, extended by rule since 2023, have waived the in-person requirement for DEA-registered practitioners who see the patient by audio-video telemedicine, and the fourth extension runs through December 31, 2026 (DEA, 90 FR 61301). In practice: a telehealth testosterone prescription in 2026 needs a live video visit, a DEA-registered prescriber and your state's permission; Arkansas, for one, bars physicians from prescribing scheduled drugs by telemedicine without an in-person exam or another listed relationship (CCHP). From January 2027 the rules depend on whether DEA extends the flexibilities again or finalizes its special registration; the parent hub tracks that.

Human growth hormone is not scheduled but is more restricted still: distributing it for anything other than an FDA-recognized disease is a federal crime, so no telehealth program can lawfully prescribe it for anti-aging.

What to ask before you pay

• Is this compound legally compoundable right now, and on what basis? A ten-second answer: approved drug, approved-drug component, USP monograph, bulks list or FDA's interim Category 1 policy.
• Which pharmacy will fill it, in which state, and is it licensed in mine?
• Who is the prescriber, and where is the license?
• Will there be a live visit and labs, and what result would make you stop?

Bottom line

Telehealth can prescribe exactly what an office clinician can: approved peptide drugs and the peptides a licensed pharmacy may compound, which in October 2026 means the GLP-1s, brand tesamorelin, sermorelin, bremelanotide, glutathione and NAD+. It cannot prescribe BPC-157, TB-500 or the other non-compoundable peptides anywhere, whatever an advisory committee recommended. The state you are in decides who may prescribe and whether a questionnaire is enough, and testosterone follows federal controlled-substance rules that change at the end of 2026.

Frequently asked questions

+−Can telehealth prescribe peptides?

Yes, for peptides that are FDA-approved or that a licensed pharmacy may legally compound: semaglutide and tirzepatide (brand, or compounded only for a documented individual need), tesamorelin (brand Egrifta only), sermorelin, bremelanotide (PT-141), glutathione and NAD+. The clinician must be licensed in the state where you are during the visit, and some states require a live visit first. No telehealth service can legally prescribe BPC-157, TB-500, CJC-1295, ipamorelin or MOTS-c in October 2026.

+−Can sermorelin be prescribed?

Yes. Sermorelin was the active ingredient of an FDA-approved drug (Geref) that was withdrawn in 2008 for commercial reasons, which makes it eligible for compounding by a state-licensed 503A pharmacy on a prescription. There is no brand product on the market, so every sermorelin prescription is filled by a compounding pharmacy. Telehealth clinicians prescribe it routinely; a responsible one checks IGF-1 first.

+−Can I get a BPC-157 prescription in the USA?

No prescription a pharmacy can legally fill. BPC-157 is not FDA-approved, has no USP monograph and is not on FDA's 503A bulks list. FDA's advisory committee voted 8 to 6 in July 2026 to recommend adding it, but nothing changes until FDA publishes a final rule, which had not happened as of October 2026. A clinic that sells it with a consultation is supplying a research vial.

+−Can I get PT-141 prescribed online?

Yes. Bremelanotide is approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and telehealth clinicians can prescribe the brand or a compounded version, including off label for men or postmenopausal women. The label contraindicates it in uncontrolled hypertension or known cardiovascular disease, so expect blood-pressure questions.

+−Is glutathione available by prescription?

Yes. FDA lists glutathione in Category 1 of its 503A nominations, which lets a licensed pharmacy compound injections on a prescription while FDA evaluates it, and telehealth programs offer it. Evidence for the uses it is sold for is weak, and FDA has repeatedly warned compounders against using dietary-supplement-grade glutathione in injectables, so ask the pharmacy what grade it uses.

+−Can telehealth prescribe testosterone?

Yes through December 31, 2026, under temporary DEA rules, after a live audio-video visit with a DEA-registered clinician; some states, such as Arkansas, are stricter. Testosterone is a Schedule III controlled substance, so the Ryan Haight Act's in-person requirement returns for new telehealth patients unless DEA extends the flexibilities or finalizes its special registration rule.

+−Why would a doctor prescribe you peptides?

For an approved use, such as semaglutide or tirzepatide for obesity or type 2 diabetes, tesamorelin for HIV-associated abdominal fat or bremelanotide for low sexual desire in premenopausal women, or off label when the evidence and your labs support it, such as sermorelin for a low IGF-1. A good reason names a goal, a measurable outcome and a stop date; a menu of peptides for everyone is not a medical reason.

Sources

1. RegulatoryFDA. Bulk drug substances used in compounding under section 503A of the FD&C Act (the 503A bulks list and interim categories).
2. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)
3. RegulatoryFDA. 2024 meeting materials, Pharmacy Compounding Advisory Committee (including summary minutes of the October 29 and December 4, 2024 meetings). (2024)
4. LabelCosette Pharmaceuticals. VYLEESI (bremelanotide injection) prescribing information, revised March 2024. DailyMed. (2024)
5. LabelTheratechnologies. EGRIFTA WR (tesamorelin) for injection: full prescribing information, revised March 2025. DailyMed. (2025)
6. Regulatory21 CFR 1308.13(f): Schedule III, anabolic steroids (testosterone listed). Electronic Code of Federal Regulations.
7. RegulatoryDrug Enforcement Administration and HHS. Fourth temporary extension of COVID-19 telemedicine flexibilities for prescription of controlled medications (effective January 1 through December 31, 2026; summarizes the Ryan Haight Act's in-person requirement). Federal Register 90 FR 61301, December 31, 2025. (2025)
8. SourceCenter for Connected Health Policy. State telehealth policies for online prescribing (state-by-state summaries of statutes and board rules). Accessed October 10, 2026. (2026)
9. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)